filgotinib vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanisms: JAK1 · JAK · full Rheumatoid Arthritis pipeline
filgotinib · Jyseleca
Marketed by Gilead Sciences and partners
NCT02873936 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).
Next expected readout: April 2029 · NCT06687551 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)
Result source: NCT02889796
upadacitinib · Rinvoq
Marketed by AbbVie
NCT02675426 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).
Next expected readout: March 2027 · NCT07636057 (registry estimate)
Reported efficacy
Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)
Result source: NCT03086343
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | filgotinib | upadacitinib |
|---|---|---|
| ACR20 | 76.6% vs 49.9%+26.7 vs placeboNCT0288979651 other results
| 63.8% vs 35.7%+28.1 vs placeboNCT0267542649 other results
|
| ACR50 | 57.9% vs 33.3%+24.6 vs placeboNCT0288979687 other results
| 52.1% vs 28.3%vs MethotrexateNCT0270687341 other results
|
| ACR70 | 36.2% vs 14.9%+21.3 vs placeboNCT0288979687 other results
| 20.8% vs 5.9%+14.9 vs placeboNCT0267542641 other results
|
| DAS28-CRP remission | 48.4% vs 16.2%+32.2 vs placeboNCT0288979635 other results
| 48.3% vs 18.5%vs MethotrexateNCT0270687322 other results
|
| HAQ-DI, change | -0.8 vs -0.6−0.2 vs placeboNCT0288979636 other results
| -0.6 vs -0.3−0.3 vs placeboNCT0267542632 other results
|
| Modified Sharp score, change | 0.1 vs 0.4−0.2 vs placeboNCT028897969 other results
| 0.1 vs 0.7vs MethotrexateNCT027068734 other results
|
ACR20
- filgotinib
- 76.6% vs 49.9%+26.7 vs placeboNCT02889796
51 other results
- 69.8% vs 49.9% NCT02889796
- 66% vs 31.1% NCT02873936
- 57.5% vs 31.1% NCT02873936
- 78.1% vs 71.4% NCT02886728
- 81% vs 71.4% NCT02886728
- 80.2% vs 71.4% NCT02886728
- 78.1% vs 59.2% NCT02889796
- 82.9% vs 86.9% NCT02889796
- 51.6% vs 31.8% NCT02889796
- 37.3% vs 14.9% NCT02889796
- 82.9% vs 85.9% NCT02889796
- 77.7% vs 59.2% NCT02889796
- 79.2% vs 86.9% NCT02889796
- 45.6% vs 31.8% NCT02889796
- 27.5% vs 14.9% NCT02889796
- 79.6% vs 85.9% NCT02889796
- 69.4% vs 34.5% NCT02873936
- 51.7% vs 25.7% NCT02873936
- 54.9% vs 34.5% NCT02873936
- 44.4% vs 25.7% NCT02873936
- 71.4% vs 59.4% NCT02886728
- 76.2% vs 68.3% NCT02886728
- 52.4% vs 33.4% NCT02886728
- 39.5% vs 16.6% NCT02886728
- 74.8% vs 61.8% NCT02886728
- 76.7% vs 59.4% NCT02886728
- 75.5% vs 68.3% NCT02886728
- 62.3% vs 33.4% NCT02886728
- 42.1% vs 16.6% NCT02886728
- 75% vs 61.8% NCT02886728
- 72% vs 59.4% NCT02886728
- 73.4% vs 68.3% NCT02886728
- 55.6% vs 33.4% NCT02886728
- 37.2% vs 16.6% NCT02886728
- 73.4% vs 61.8% NCT02886728
- 72.5% vs 29.2% NCT01894516
- 68.6% vs 44.2% NCT01888874
- 65.7% vs 29.2% NCT01894516
- 63.5% vs 44.2% NCT01888874
- 78.6% vs 44.2% NCT01888874
- 66.7% vs 29.2% NCT01894516
- 56.1% vs 44.2% NCT01888874
- 60% vs 44.2% NCT01888874
- 57% vs 44.2% NCT01888874
- 73.3% vs 41.9% NCT01888874
- 61.2% vs 41.9% NCT01888874
- 79.8% vs 41.9% NCT01888874
- 54.9% vs 41.9% NCT01888874
- 60% vs 41.9% NCT01888874
- 55.8% vs 41.9% NCT01888874
- 81% vs 40.9% NCT02885181
- upadacitinib
- 63.8% vs 35.7%+28.1 vs placeboNCT02675426
49 other results
- 64.6% vs 28.4% NCT02706847
- 71.6% vs 31.4% NCT02955212
- 66.2% vs 35.7% NCT02675426
- 56.4% vs 28.4% NCT02706847
- 83.7% vs 42.9% NCT02720523
- 80% vs 42.9% NCT02720523
- 75.5% vs 42.9% NCT02720523
- 67.7% vs 41.2% NCT02706951
- 75.7% vs 54.1% NCT02706873
- 71.2% vs 41.2% NCT02706951
- 77.1% vs 54.1% NCT02706873
- 22.2% vs 8.6% NCT02675426
- 27.4% vs 10.7% NCT02706847
- 25.4% vs 5.9% NCT02955212
- 28.3% vs 8.6% NCT02675426
- 24.8% vs 10.7% NCT02706847
- 24.5% vs 8.2% NCT02720523
- 34% vs 8.2% NCT02720523
- 30.6% vs 8.2% NCT02720523
- 78.9% vs 58.6% NCT02706873
- 78% vs 58.6% NCT02706873
- 85.2% vs 57.1% NCT02706873
- 78.6% vs 57.1% NCT02706873
- 85.5% vs 57.1% NCT02706873
- 81.6% vs 50% NCT02066389
- 76.6% vs 50% NCT02066389
- 70.9% vs 35.2% NCT01960855
- 81.6% vs 50% NCT02066389
- 72.7% vs 35.2% NCT01960855
- 73.5% vs 50% NCT02066389
- 63.5% vs 35.2% NCT01960855
- 64.6% vs 50% NCT02066389
- 55.6% vs 35.2% NCT01960855
- 41.5% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 29.3% vs 42.1% NCT03682705
- 24.4% vs 21.1% NCT03682705
- 30.8% vs 47.4% NCT03682705
- 30.8% vs 36.8% NCT03682705
- 23.1% vs 42.1% NCT03682705
- 12.8% vs 21.1% NCT03682705
- 64.5% vs 47.4% NCT03682705
- 64.5% vs 36.8% NCT03682705
- 51.6% vs 42.1% NCT03682705
- 45.2% vs 21.1% NCT03682705
- 34.1% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 22% vs 42.1% NCT03682705
- 14.6% vs 21.1% NCT03682705
ACR50
- filgotinib
- 57.9% vs 33.3%+24.6 vs placeboNCT02889796
87 other results
- 47.2% vs 19.8% NCT02889796
- 63.2% vs 63.4% NCT02889796
- 22.3% vs 5.9% NCT02889796
- 9.1% vs 1.1% NCT02889796
- 64.2% vs 66% NCT02889796
- 52.7% vs 33.3% NCT02889796
- 36.5% vs 19.8% NCT02889796
- 57.7% vs 63.4% NCT02889796
- 12.9% vs 5.9% NCT02889796
- 5.8% vs 1.1% NCT02889796
- 60.6% vs 66% NCT02889796
- 45.6% vs 18.9% NCT02873936
- 42.9% vs 14.9% NCT02873936
- 22.4% vs 7.4% NCT02873936
- 35.3% vs 18.9% NCT02873936
- 32% vs 14.9% NCT02873936
- 21.6% vs 7.4% NCT02873936
- 58.1% vs 45.7% NCT02886728
- 45.7% vs 28.4% NCT02886728
- 58.6% vs 48.6% NCT02886728
- 25.7% vs 9.4% NCT02886728
- 16.2% vs 2.9% NCT02886728
- 61.4% vs 48.3% NCT02886728
- 61.5% vs 45.7% NCT02886728
- 53.1% vs 28.4% NCT02886728
- 60.6% vs 48.6% NCT02886728
- 29.3% vs 9.4% NCT02886728
- 13% vs 2.9% NCT02886728
- 62.3% vs 48.3% NCT02886728
- 57% vs 45.7% NCT02886728
- 44.4% vs 28.4% NCT02886728
- 55.6% vs 48.6% NCT02886728
- 20.8% vs 9.4% NCT02886728
- 9.2% vs 2.9% NCT02886728
- 59.4% vs 48.3% NCT02886728
- 50% vs 16.3% NCT01888874
- 43.5% vs 11.1% NCT01894516
- 43% vs 15.1% NCT01888874
- 31.9% vs 5.6% NCT01894516
- 33.7% vs 12.8% NCT01888874
- 23.2% vs 4.2% NCT01894516
- 17.4% vs 7% NCT01888874
- 21.7% vs 4.2% NCT01894516
- 10.5% vs 5.8% NCT01888874
- 7.2% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 47.1% vs 16.3% NCT01888874
- 54.8% vs 16.3% NCT01888874
- 37.1% vs 11.1% NCT01894516
- 37.6% vs 15.1% NCT01888874
- 54.8% vs 15.1% NCT01888874
- 25.7% vs 5.6% NCT01894516
- 35.3% vs 12.8% NCT01888874
- 45.2% vs 12.8% NCT01888874
- 18.6% vs 4.2% NCT01894516
- 32.9% vs 7% NCT01888874
- 34.5% vs 7% NCT01888874
- 7.1% vs 4.2% NCT01894516
- 20% vs 5.8% NCT01888874
- 21.4% vs 5.8% NCT01888874
- 10% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 35.4% vs 16.3% NCT01888874
- 35.3% vs 16.3% NCT01888874
- 34.7% vs 11.1% NCT01894516
- 32.9% vs 15.1% NCT01888874
- 34.1% vs 15.1% NCT01888874
- 16.7% vs 5.6% NCT01894516
- 26.8% vs 12.8% NCT01888874
- 34.1% vs 12.8% NCT01888874
- 15.3% vs 4.2% NCT01894516
- 13.4% vs 7% NCT01888874
- 18.8% vs 7% NCT01888874
- 5.6% vs 4.2% NCT01894516
- 7.3% vs 5.8% NCT01888874
- 11.8% vs 5.8% NCT01888874
- 1.4% vs 1.4% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 34.9% vs 16.3% NCT01888874
- 27.9% vs 15.1% NCT01888874
- 25.6% vs 12.8% NCT01888874
- 15.1% vs 7% NCT01888874
- 7% vs 5.8% NCT01888874
- 3.5% vs 1.2% NCT01888874
- 47.6% vs 22.7% NCT02885181
- upadacitinib
- 52.1% vs 28.3%vs MethotrexateNCT02706873
41 other results
- 56.4% vs 28.3% NCT02706873
- 38% vs 14.9% NCT02675426
- 34.1% vs 11.8% NCT02706847
- 40.8% vs 8.3% NCT02955212
- 43.4% vs 14.9% NCT02675426
- 35.8% vs 11.8% NCT02706847
- 65.3% vs 16.3% NCT02720523
- 58% vs 16.3% NCT02720523
- 40.8% vs 16.3% NCT02720523
- 60.3% vs 33.4% NCT02706873
- 41.9% vs 15.3% NCT02706951
- 65.6% vs 33.4% NCT02706873
- 52.1% vs 15.3% NCT02706951
- 66.7% vs 21.4% NCT02706873
- 71.4% vs 21.4% NCT02706873
- 60% vs 21.4% NCT02706873
- 29.3% vs 21.1% NCT03682705
- 19.5% vs 5.3% NCT03682705
- 17.1% vs 10.5% NCT03682705
- 4.9% vs 0% NCT03682705
- 43.8% vs 19.6% NCT02066389
- 12.8% vs 21.1% NCT03682705
- 12.8% vs 5.3% NCT03682705
- 2.6% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 44.7% vs 19.6% NCT02066389
- 40% vs 17% NCT01960855
- 45.2% vs 21.1% NCT03682705
- 41.9% vs 5.3% NCT03682705
- 19.4% vs 10.5% NCT03682705
- 16.1% vs 0% NCT03682705
- 50% vs 19.6% NCT02066389
- 43.6% vs 17% NCT01960855
- 49% vs 19.6% NCT02066389
- 38.5% vs 17% NCT01960855
- 17.1% vs 21.1% NCT03682705
- 7.3% vs 5.3% NCT03682705
- 4.9% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 39.6% vs 19.6% NCT02066389
- 24.1% vs 17% NCT01960855
ACR70
- filgotinib
- 36.2% vs 14.9%+21.3 vs placeboNCT02889796
87 other results
- 26.1% vs 6.7% NCT02889796
- 40.2% vs 34.6% NCT02889796
- 9.1% vs 1.5% NCT02889796
- 2.7% vs 0.4% NCT02889796
- 44.4% vs 37.7% NCT02889796
- 29.6% vs 14.9% NCT02889796
- 18.5% vs 6.7% NCT02889796
- 35.4% vs 34.6% NCT02889796
- 3.3% vs 1.5% NCT02889796
- 1.3% vs 0.4% NCT02889796
- 39% vs 37.7% NCT02889796
- 32% vs 8.1% NCT02873936
- 21.8% vs 6.8% NCT02873936
- 6.1% vs 2.7% NCT02873936
- 20.3% vs 8.1% NCT02873936
- 14.4% vs 6.8% NCT02873936
- 8.5% vs 2.7% NCT02873936
- 40% vs 26% NCT02886728
- 29% vs 13.2% NCT02886728
- 39.5% vs 32.2% NCT02886728
- 11.4% vs 3.8% NCT02886728
- 4.3% vs 0.7% NCT02886728
- 45.2% vs 29.8% NCT02886728
- 43.8% vs 26% NCT02886728
- 32.9% vs 13.2% NCT02886728
- 45.9% vs 32.2% NCT02886728
- 13% vs 3.8% NCT02886728
- 3.1% vs 0.7% NCT02886728
- 47.8% vs 29.8% NCT02886728
- 40.1% vs 26% NCT02886728
- 27.1% vs 13.2% NCT02886728
- 37.2% vs 32.2% NCT02886728
- 6.3% vs 3.8% NCT02886728
- 1.9% vs 0.7% NCT02886728
- 40.1% vs 29.8% NCT02886728
- 29.1% vs 9.3% NCT01888874
- 13% vs 2.8% NCT01894516
- 24.4% vs 8.1% NCT01888874
- 17.4% vs 2.8% NCT01894516
- 18.6% vs 7% NCT01888874
- 11.6% vs 1.4% NCT01894516
- 4.7% vs 3.5% NCT01888874
- 4.3% vs 2.8% NCT01894516
- 5.8% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 1.2% vs 1.2% NCT01888874
- 32.9% vs 9.3% NCT01888874
- 39.3% vs 9.3% NCT01888874
- 18.6% vs 2.8% NCT01894516
- 21.2% vs 8.1% NCT01888874
- 31% vs 8.1% NCT01888874
- 11.4% vs 2.8% NCT01894516
- 23.5% vs 7% NCT01888874
- 27.4% vs 7% NCT01888874
- 5.7% vs 1.4% NCT01894516
- 14.1% vs 3.5% NCT01888874
- 10.7% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 7.1% vs 1.2% NCT01888874
- 3.6% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 4.8% vs 1.2% NCT01888874
- 22% vs 9.3% NCT01888874
- 23.5% vs 9.3% NCT01888874
- 8.3% vs 2.8% NCT01894516
- 15.9% vs 8.1% NCT01888874
- 18.8% vs 8.1% NCT01888874
- 6.9% vs 2.8% NCT01894516
- 11% vs 7% NCT01888874
- 14.1% vs 7% NCT01888874
- 8.3% vs 1.4% NCT01894516
- 7.3% vs 3.5% NCT01888874
- 9.4% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 5.9% vs 1.2% NCT01888874
- 0% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 2.4% vs 1.2% NCT01888874
- 20.9% vs 9.3% NCT01888874
- 14% vs 8.1% NCT01888874
- 9.3% vs 7% NCT01888874
- 5.8% vs 3.5% NCT01888874
- 2.3% vs 1.2% NCT01888874
- 1.2% vs 1.2% NCT01888874
- 38.1% vs 13.6% NCT02885181
- upadacitinib
- 20.8% vs 5.9%+14.9 vs placeboNCT02675426
41 other results
- 11.6% vs 6.5% NCT02706847
- 21.3% vs 3.6% NCT02955212
- 26.5% vs 5.9% NCT02675426
- 23% vs 6.5% NCT02706847
- 34.7% vs 2% NCT02720523
- 28% vs 2% NCT02720523
- 20.4% vs 2% NCT02720523
- 44.5% vs 18.5% NCT02706873
- 22.6% vs 2.8% NCT02706951
- 32.5% vs 14% NCT02706873
- 49.7% vs 18.5% NCT02706873
- 33% vs 2.8% NCT02706951
- 36.9% vs 14% NCT02706873
- 51.9% vs 0% NCT02706873
- 64.3% vs 0% NCT02706873
- 34.5% vs 0% NCT02706873
- 14.6% vs 15.8% NCT03682705
- 4.9% vs 0% NCT03682705
- 4.9% vs 0% NCT03682705
- 2.4% vs 0% NCT03682705
- 25% vs 6.5% NCT02066389
- 5.1% vs 15.8% NCT03682705
- 2.6% vs 0% NCT03682705
- 2.6% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 27.7% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 25.8% vs 15.8% NCT03682705
- 17.7% vs 0% NCT03682705
- 9.7% vs 0% NCT03682705
- 8.1% vs 0% NCT03682705
- 16% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 30.6% vs 6.5% NCT02066389
- 26.9% vs 3.6% NCT01960855
- 9.8% vs 15.8% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 23.4% vs 6.5% NCT02066389
- 13% vs 3.6% NCT01960855
DAS28-CRP remission
- filgotinib
- 48.4% vs 16.2%+32.2 vs placeboNCT02889796
35 other results
- 34.1% vs 9.3% NCT02889796
- 50.3% vs 46.1% NCT02889796
- 13.7% vs 2.9% NCT02889796
- 5.1% vs 0.6% NCT02889796
- 54.5% vs 50.8% NCT02889796
- 35.2% vs 16.2% NCT02889796
- 23.8% vs 9.3% NCT02889796
- 42.9% vs 46.1% NCT02889796
- 8.8% vs 2.9% NCT02889796
- 1.7% vs 0.6% NCT02889796
- 44.8% vs 50.8% NCT02889796
- 30.6% vs 12.2% NCT02873936
- 22.4% vs 8.1% NCT02873936
- 10.2% vs 2.7% NCT02873936
- 26.1% vs 12.2% NCT02873936
- 25.5% vs 8.1% NCT02873936
- 11.8% vs 2.7% NCT02873936
- 42.4% vs 29.1% NCT02886728
- 29.5% vs 17.1% NCT02886728
- 43.3% vs 34.4% NCT02886728
- 19.5% vs 4.8% NCT02886728
- 10% vs 1% NCT02886728
- 46.2% vs 31.5% NCT02886728
- 54.1% vs 29.1% NCT02886728
- 39.7% vs 17.1% NCT02886728
- 52.6% vs 34.4% NCT02886728
- 16.6% vs 4.8% NCT02886728
- 7.2% vs 1% NCT02886728
- 53.4% vs 31.5% NCT02886728
- 42.5% vs 29.1% NCT02886728
- 31.9% vs 17.1% NCT02886728
- 42% vs 34.4% NCT02886728
- 15% vs 4.8% NCT02886728
- 4.3% vs 1% NCT02886728
- 43% vs 31.5% NCT02886728
- upadacitinib
- 48.3% vs 18.5%vs MethotrexateNCT02706873
22 other results
- 50% vs 18.5% NCT02706873
- 30.8% vs 10% NCT02675426
- 29.6% vs 5.3% NCT02955212
- 28.3% vs 10% NCT02675426
- 57.1% vs 6.1% NCT02720523
- 50% vs 6.1% NCT02720523
- 36.7% vs 6.1% NCT02720523
- 28.1% vs 8.3% NCT02706951
- 30% vs 13.3% NCT03086343
- 40.5% vs 8.3% NCT02706951
- 70.4% vs 17.9% NCT02706873
- 82.1% vs 17.9% NCT02706873
- 67.3% vs 17.9% NCT02706873
- 19.5% vs 10.5% NCT03682705
- 22.4% vs 14.9% NCT02066389
- 7.7% vs 10.5% NCT03682705
- 42.9% vs 14.9% NCT02066389
- 32.3% vs 10.5% NCT03682705
- 34% vs 14.9% NCT02066389
- 38.8% vs 14.9% NCT02066389
- 9.8% vs 10.5% NCT03682705
- 36.7% vs 14.9% NCT02066389
HAQ-DI, change
- filgotinib
- -0.8 vs -0.6−0.2 vs placeboNCT02889796
36 other results
- -0.7 vs -0.4 NCT02889796
- -0.9 vs -0.7 NCT02889796
- -0.4 vs -0.3 NCT02889796
- -0.3 vs -0.1 NCT02889796
- -0.9 vs -0.7 NCT02889796
- -0.8 vs -0.6 NCT02889796
- -0.6 vs -0.4 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.3 vs -0.3 NCT02889796
- -0.2 vs -0.1 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.8 vs -0.4 NCT02873936
- -0.6 vs -0.2 NCT02873936
- -0.4 vs -0.2 NCT02873936
- -0.6 vs -0.4 NCT02873936
- -0.5 vs -0.2 NCT02873936
- -0.3 vs -0.2 NCT02873936
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.3 vs -0.2 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.6 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -1 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.7 vs -0.4 NCT02885181
- upadacitinib
- -0.6 vs -0.3−0.3 vs placeboNCT02675426
32 other results
- -0.4 vs -0.2 NCT02706847
- -0.6 vs -0.2 NCT02955212
- -0.5 vs -0.3 NCT02675426
- -0.4 vs -0.2 NCT02706847
- -0.5 vs -0.1 NCT02720523
- -0.5 vs -0.1 NCT02720523
- -0.4 vs -0.1 NCT02720523
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.8 vs -0.5 NCT02706873
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.9 vs -0.5 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.8 vs -0.2 NCT02706873
- -0.3 vs -0.3 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.5 vs -0.3 NCT03682705
- -0.5 vs -0.2 NCT03682705
- -0.4 vs -0.4 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.2 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.2 vs -0.4 NCT03682705
- -0.2 vs -0.2 NCT03682705
Modified Sharp score, change
- filgotinib
- 0.1 vs 0.4−0.2 vs placeboNCT02889796
9 other results
- 0.2 vs 0.9 NCT02889796
- 0.2 vs 0.4 NCT02889796
- 0.5 vs 0.9 NCT02889796
- -0.0 vs 0.5 NCT02886728
- 0.3 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- 0.3 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- 0.2 vs 0.8 NCT02886728
- upadacitinib
- 0.1 vs 0.7vs MethotrexateNCT02706873
4 other results
- 0.1 vs 0.7 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.9 vs 2.6 NCT02706873
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
14 other shared endpoints and safety
Coverage. filgotinib: 18 of 18 rows · upadacitinib: 18 of 18 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | filgotinib Rows use multiple source trials | upadacitinib Rows use multiple source trials |
|---|---|---|
| Boolean Remission responder rate · % of participants | 4.3% (n=69) vs 1.4% (n=72) placebo @ 12wk200 mg QDa,b NCT01894516 · Phase 2 · registry result, not featured evidence show 2 more doses4.3% (n=70) vs 1.4% (n=72) placebo @ 12wk100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 1.4% (n=72) vs 1.4% (n=72) placebo @ 12wk50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence | 9.8% (n=41) vs 0% (n=19) placebo @ 12wk60 mga,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses2.6% (n=39) vs 0% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 11.3% (n=62) vs 0% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4% (n=41) vs 0% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| CDAI absolute change · score | -26.2 vs -17.3 placebo score @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-23.8 vs -17.3 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -17.5 vs -14.57 placebo score @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-16.7 vs -14.57 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -27 vs -14.57 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.51 vs -14.57 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| CRP Change absolute change · mg | -11.86 vs 0.57 placebo mg @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-12.02 vs 0.57 placebo mg @ 12wk100 mg NCT02873936 · Phase 3 | -4.58 vs 1.45 placebo mg @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-5.78 vs 1.45 placebo mg @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -10.95 vs 1.45 placebo mg @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -0.81 vs 1.45 placebo mg @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| DAS Low Disease Activity responder rate · % of participants | 48.3% (n=147) vs 20.9% (n=148) placebo @ 24wk200 mga,b,d NCT02873936 · Phase 3 show 1 more dose37.9% (n=153) vs 20.9% (n=148) placebo @ 24wk100 mg NCT02873936 · Phase 3 | 59.9% (n=317) vs 32.2% (n=314) Methotrexate @ 24wk15 mga,b,d NCT02706873 · Phase 3 show 1 more dose65% (n=314) vs 32.2% (n=314) Methotrexate @ 24wk30 mg NCT02706873 · Phase 3 |
| DAS28-CRP absolute change · score | -2.9 vs -2.1 placebo score @ 24wk200 mga,b,d NCT02873936 · Phase 3 show 1 more dose-2.6 vs -2.1 placebo score @ 24wk100 mg NCT02873936 · Phase 3 | -3.07 vs -2.15 Methotrexate score @ 24wk15 mga,b,d NCT02706873 · Phase 3 show 1 more dose-3.34 vs -2.15 Methotrexate score @ 24wk30 mg NCT02706873 · Phase 3 |
| FACIT-Fatigue absolute change · score | 9.6 vs 4.5 placebo score @ 12wk200 mga,b,d NCT02873936 · Phase 3 show 1 more dose8.3 vs 4.5 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | 7.91 vs 2.96 placebo score @ 12wk15 mga,b,d NCT02675426 · Phase 3 show 1 more dose7.74 vs 2.96 placebo score @ 12wk30 mg NCT02675426 · Phase 3 |
| HAQ-DI responder rate · % of participants | 78.9% (n=475) vs 57.9% (n=475) placebo @ 12wk200 mga,c,b NCT02889796 · Phase 3 show 1 more dose71.5% (n=480) vs 57.9% (n=475) placebo @ 12wk100 mg NCT02889796 · Phase 3 | 53.7% (n=41) vs 47.4% (n=19) placebo @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses43.6% (n=39) vs 47.4% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 58.1% (n=62) vs 47.4% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 43.9% (n=41) vs 47.4% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Patient Assessment of Arthritis Pain absolute change · score | -30 vs -14 placebo score @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-27 vs -14 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -19.52 vs -23.37 placebo score @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-10.46 vs -23.37 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -32.27 vs -23.37 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -17.84 vs -23.37 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Patient Global Assessment absolute change · score | -31 vs -14 placebo score @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-27 vs -14 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -19.47 vs -19.55 placebo score @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-8.45 vs -19.55 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -30.52 vs -19.55 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.4 vs -19.55 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Physician Global Assessment absolute change · score | -45 vs -28 placebo score @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-41 vs -28 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -30.15 vs -23.19 placebo score @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-31.68 vs -23.19 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -46.98 vs -23.19 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -24.55 vs -23.19 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| SDAI absolute change · score | -27.6 vs -17.2 placebo score @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-24.9 vs -17.2 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -18.01 vs -14.44 placebo score @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-17.12 vs -14.44 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -28.06 vs -14.44 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.73 vs -14.44 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| SF-36 PCS absolute change · score | 9.4 vs 6.6 placebo score @ 24wk200 mga,b,d NCT02873936 · Phase 3 show 1 more dose9 vs 6.6 placebo score @ 24wk100 mg NCT02873936 · Phase 3 | 10.7 vs 6.97 Methotrexate score @ 24wk15 mga,b,d NCT02706873 · Phase 3 show 1 more dose11.39 vs 6.97 Methotrexate score @ 24wk30 mg NCT02706873 · Phase 3 |
| Swollen Joint Count absolute change · count | -12 vs -8 placebo count @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-10 vs -8 placebo count @ 12wk100 mg NCT02873936 · Phase 3 | -6.68 vs -5.58 placebo count @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-7.85 vs -5.58 placebo count @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -10.86 vs -5.58 placebo count @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -8.59 vs -5.58 placebo count @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Tender Joint Count absolute change · count | -18 vs -12 placebo count @ 12wk200 mga,c,b NCT02873936 · Phase 3 show 1 more dose-16 vs -12 placebo count @ 12wk100 mg NCT02873936 · Phase 3 | -9.14 vs -8.47 placebo count @ 12wk60 mga,c,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-9.33 vs -8.47 placebo count @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -16.33 vs -8.47 placebo count @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -12.58 vs -8.47 placebo count @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 8.8%200 mge NCT02873936 · Phase 3 show 26 more results15%100 mg NCT02873936 · Phase 3 17.1%200 mg NCT02886728 · Phase 3 · monotherapy 17.3%200 mg NCT02886728 · Phase 3 · combination 15.5%100 mg NCT02886728 · Phase 3 · combination 11.1%200 mg NCT02889796 · Phase 3 12.1%100 mg NCT02889796 · Phase 3 52.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53.7%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 61.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 0%Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 67.6%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 66.5%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 4.3%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 6.9%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 7%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 8.2%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 5.9%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 7.3%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 10.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | —15 mge NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.6%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 8.2%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 12.6%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 14%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 7.3%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 7.4%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 4.7%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 4.8%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 9.7%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 4.1%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 12%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 7.3%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 12.8%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 6.5%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 14.6%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 10%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 14%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 6%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 12%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 9.1%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 16.4%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2%200 mge NCT02873936 · Phase 3 show 26 more results3.3%100 mg NCT02873936 · Phase 3 2.4%200 mg NCT02886728 · Phase 3 · monotherapy 3.1%200 mg NCT02886728 · Phase 3 · combination 2.4%100 mg NCT02886728 · Phase 3 · combination 3.6%200 mg NCT02889796 · Phase 3 1.7%100 mg NCT02889796 · Phase 3 12.3%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 13.4%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 14%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 12.2%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 33.2%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 42.6%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 1.4%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 1.2%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 2.4%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | —15 mge NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 1.4%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 4.1%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 5.7%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 3.5%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 5.5%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 2.3%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 1.4%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 0.6%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 2.4%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 1.6%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 2%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 10%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 3.6%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 10.9%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.1%200 mge NCT02873936 · Phase 3 show 26 more results5.2%100 mg NCT02873936 · Phase 3 8.1%200 mg NCT02886728 · Phase 3 · monotherapy 6.3%200 mg NCT02886728 · Phase 3 · combination 6.3%100 mg NCT02886728 · Phase 3 · combination 7.4%200 mg NCT02889796 · Phase 3 8.3%100 mg NCT02889796 · Phase 3 24.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 22.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 24.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 25.9%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 3.7%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 12.8%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 14.3%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 16.9%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 19.8%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.8%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.3%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.6%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.4%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 2.3%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | 28.1%15 mge NCT02675426 · Phase 3 show 55 more results4.5%15 mg NCT02675426 · Phase 3 10.6%15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.2%30 mg NCT02675426 · Phase 3 31.8%30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 15.5%15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 5%15 mg NCT02706873 · Phase 3 · monotherapy 21.5%15 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 6.4%30 mg NCT02706873 · Phase 3 · monotherapy 22.6%30 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 9.1%7.5 mg NCT02706873 · Phase 3 · monotherapy 23.6%7.5 mg NCT02706873 · Phase 3 · monotherapy 4%15 mg QD NCT03086343 · Phase 3 23.6%15 mg QD NCT03086343 · Phase 3 19%30 mg QD NCT03086343 · Phase 3 35.3%30 mg QD NCT03086343 · Phase 3 5.1%15 mg NCT02706951 · Phase 3 10.7%15 mg NCT02706951 · Phase 3 29.9%15 mg NCT02706951 · Phase 3 2.8%30 mg NCT02706951 · Phase 3 24.1%30 mg NCT02706951 · Phase 3 —15 mg NCT02706847 · Phase 3 15.2%15 mg NCT02706847 · Phase 3 5.5%15 mg NCT02706847 · Phase 3 36.9%15 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 29.6%30 mg NCT02706847 · Phase 3 17.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 7.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 21.9%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 27.3%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 13.8%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 22.5%12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 13.8%6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 0%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 5.1%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 4.1%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 6%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 4%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 1.8%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 mge nasopharyngitis 10.2% (placebo 4.7%) bronchitis 5.4% (placebo 5.4%) headache 5.4% (placebo 1.4%) NCT02873936 · Phase 3 show 25 more results100 mg headache 5.9% (placebo 1.4%) nasopharyngitis 5.9% (placebo 4.7%) upper respiratory tract infection 5.9% (placebo 4.1%) NCT02873936 · Phase 3 200 mg nausea 12.3% upper respiratory tract infection 10.1% alanine aminotransferase increased 5.5% NCT02886728 · Phase 3 · combination 200 mg nasopharyngitis 9.1% (placebo 5.3%) upper respiratory tract infection 8.6% (placebo 2.9%) nausea 5.5% (placebo 1.5%) NCT02889796 · Phase 3 100 mg upper respiratory tract infection 10.2% (placebo 2.9%) nasopharyngitis 10% (placebo 5.3%) alanine aminotransferase increased 5.2% (placebo 2.3%) NCT02889796 · Phase 3 200 mg covid-19 18.3% nasopharyngitis 13.1% upper respiratory tract infection 11% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg covid-19 17.3% upper respiratory tract infection 13.1% rheumatoid arthritis 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 15.3% nasopharyngitis 15.1% rheumatoid arthritis 13.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 18.5% rheumatoid arthritis 12.2% upper respiratory tract infection 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 7.4% (placebo 7.3%) dyslipidaemia 3.7% (placebo 0%) headache 3.7% (placebo 1.8%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg covid-19 15.4% (placebo 0%) ankylosing spondylitis 7.7% (placebo 0%) latent tuberculosis 7.7% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 57.1% (placebo 7.3%) covid-19 42.9% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence hypertension 15.1% urinary tract infection 14.5% nasopharyngitis 14.1% NCT02065700 · Phase 2 · registry result, not featured evidence mycobacterium tuberculosis complex test positive 16.5% upper respiratory tract infection 15.3% hypercholesterolaemia 12.4% NCT02065700 · Phase 2 · registry result, not featured evidence asthenia 9.5% (placebo 0%) blood creatine phosphokinase increased 4.8% (placebo 0%) dyspepsia 4.8% (placebo 0%) NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 200 mg QD anaemia 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 2.8%) urinary tract infection 5.8% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 100 mg QD urinary tract infection 8.2% (placebo 1.4%) hypercholesterolaemia 5.9% (placebo 4.2%) hypertriglyceridaemia 5.9% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 50 mg QD headache 5.6% (placebo 1.4%) hypercholesterolaemia 5.6% (placebo 4.2%) hypertension 4.2% (placebo 5.6%) NCT01894516 · Phase 2 · registry result, not featured evidence 200 mg QD headache 7% (placebo 4.7%) hypercholesterolaemia 5.8% (placebo 0%) hypertension 4.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg BID hypercholesterolaemia 4.8% (placebo 0%) nasopharyngitis 4.8% (placebo 4.7%) headache 2.4% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg QD hypertension 5% (placebo 2.3%) nasopharyngitis 2.5% (placebo 4.7%) upper respiratory tract infection 1.7% (placebo 1.2%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg BID upper respiratory tract infection 5.1% (placebo 1.2%) vomiting 5.1% (placebo 1.2%) hypertension 3.4% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 9.8% (placebo 4.7%) nausea 8.5% (placebo 3.5%) hypertension 3.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 25 mg BID headache 7% (placebo 4.7%) gastroenteritis 5.8% (placebo 0%) nasopharyngitis 4.7% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence | 15 mge upper respiratory tract infection 19.8% (placebo 4.1%) nasopharyngitis 18.5% (placebo 4.1%) urinary tract infection 17% (placebo 3.6%) NCT02675426 · Phase 3 show 48 more results15 mg nausea 6.8% (placebo 3.2%) nasopharyngitis 5.4% (placebo 4.1%) upper respiratory tract infection 5.4% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 8.9% (placebo 0%) rheumatoid arthritis 4.5% (placebo 4.5%) fall 2.8% (placebo 0.5%) NCT02675426 · Phase 3 30 mg nasopharyngitis 5.9% (placebo 4.1%) upper respiratory tract infection 5.5% (placebo 4.1%) headache 3.7% (placebo 5.4%) NCT02675426 · Phase 3 30 mg upper respiratory tract infection 17.8% (placebo 4.1%) urinary tract infection 14.3% (placebo 3.6%) nasopharyngitis 14% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 10.5% rheumatoid arthritis 9.4% urinary tract infection 7.2% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 6.3% nasopharyngitis 5.7% nausea 5.7% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 15.5% nasopharyngitis 15.1% urinary tract infection 13.6% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 10.8% upper respiratory tract infection 7.3% urinary tract infection 5.7% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 16.2% nasopharyngitis 16.2% hypertension 14% NCT02706873 · Phase 3 · monotherapy 15 mg QD upper respiratory tract infection 8.6% nasopharyngitis 7.3% urinary tract infection 6.6% NCT03086343 · Phase 3 30 mg QD hypertension 23.5% upper respiratory tract infection 23.5% bronchitis 17.6% NCT03086343 · Phase 3 15 mg urinary tract infection 4.6% upper respiratory tract infection 4.1% blood creatine phosphokinase increased 2.3% NCT02706951 · Phase 3 15 mg nasopharyngitis 17.6% rheumatoid arthritis 14.2% urinary tract infection 13.5% NCT02706951 · Phase 3 30 mg urinary tract infection 4.7% blood creatine phosphokinase increased 4.2% upper respiratory tract infection 2.8% NCT02706951 · Phase 3 30 mg blood creatine phosphokinase increased 18.6% urinary tract infection 15.1% upper respiratory tract infection 14.8% NCT02706951 · Phase 3 15 mg rheumatoid arthritis 9.4% (placebo 5.9%) urinary tract infection 8% (placebo 5.9%) back pain 5.8% (placebo 2.4%) NCT02706847 · Phase 3 15 mg urinary tract infection 9.8% (placebo 5.9%) upper respiratory tract infection 7.9% (placebo 7.7%) bronchitis 4.3% (placebo 2.4%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 31.4% (placebo 7.7%) urinary tract infection 18.2% (placebo 5.9%) nasopharyngitis 14.4% (placebo 6.5%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 6.7% (placebo 7.7%) nasopharyngitis 5.5% (placebo 6.5%) urinary tract infection 5.5% (placebo 5.9%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 27.9% (placebo 7.7%) urinary tract infection 20.4% (placebo 5.9%) nasopharyngitis 17.1% (placebo 6.5%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 20.2% (placebo 6.5%) alanine aminotransferase increased 9.3% (placebo 1.2%) blood creatine phosphokinase increased 9% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 9.5% (placebo 6.5%) alanine aminotransferase increased 5.3% (placebo 1.2%) anaemia 0% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg nasopharyngitis 54.7% (placebo 10.2%) herpes zoster 14.1% (placebo 2%) influenza 14.1% (placebo 4.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 15 mg nasopharyngitis 12.2% (placebo 10.2%) liver function test increased 6.1% (placebo 0%) constipation 4.1% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 43.9% (placebo 10.2%) constipation 15.2% (placebo 0%) herpes zoster 15.2% (placebo 2%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 18% (placebo 10.2%) blood creatine phosphokinase increased 6% (placebo 0%) headache 6% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 53.8% (placebo 10.2%) stomatitis 20% (placebo 6.1%) hypertension 12.3% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 10.2% (placebo 10.2%) hypertension 6.1% (placebo 0%) stomatitis 6.1% (placebo 6.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 12 mg BID/30 mg QD upper respiratory tract infection 20.3% urinary tract infection 15% herpes zoster 11.2% NCT02049138 · Phase 2 · registry result, not featured evidence 6 mg BID/15 mg QD upper respiratory tract infection 9.9% nasopharyngitis 9.5% urinary tract infection 9.5% NCT02049138 · Phase 2 · registry result, not featured evidence 60 mg urinary tract infection 9.8% (placebo 0%) diarrhoea 7.3% (placebo 0%) rheumatoid arthritis 7.3% (placebo 10.5%) NCT03682705 · Phase 2 · registry result, not featured evidence 20 mg rheumatoid arthritis 7.7% (placebo 10.5%) upper respiratory tract infection 7.7% (placebo 5.3%) alopecia 5.1% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 15 mg/60 mg upper respiratory tract infection 6.5% (placebo 5.3%) arthralgia 1.6% (placebo 5.3%) cough 1.6% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence · combination 5 mg rheumatoid arthritis 7.3% (placebo 10.5%) upper respiratory tract infection 4.9% (placebo 5.3%) urinary tract infection 4.9% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 24 mg QD nasopharyngitis 6.1% (placebo 2%) back pain 2% (placebo 0%) blood creatine phosphokinase increased 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID blood creatine phosphokinase increased 4% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 12 mg BID influenza 8% (placebo 0%) nasopharyngitis 8% (placebo 2%) blood creatine phosphokinase increased 6% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 6 mg BID back pain 6% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 3 mg BID headache 4% (placebo 2%) back pain 2% (placebo 0%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID urinary tract infection 12.7% (placebo 3.6%) blood creatine phosphokinase increased 9.1% (placebo 0%) constipation 7.3% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 12 mg BID upper respiratory tract infection 7.3% (placebo 1.8%) headache 5.5% (placebo 1.8%) leukopenia 5.5% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 6 mg BID headache 5.5% (placebo 1.8%) hyperlipidaemia 3.6% (placebo 1.8%) constipation 1.8% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 3 mg BID nausea 7.3% (placebo 1.8%) arthralgia 5.5% (placebo 0%) headache 5.5% (placebo 1.8%) NCT01960855 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTrial phases differ: Phase 2 versus Phase 3.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
filgotinib
show 23 more results
show 17 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 30 more results
show 30 more results
show 30 more results
show 30 more results
+ 246 further endpoints in the CSV export.
upadacitinib
show 23 more results
show 3 more results
show 4 more results
show 2 more results
show 18 more results
show 3 more results
show 20 more results
show 15 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · upadacitinib's landscape